Imaging Focal Hypoxia in Diabetic Retinopathy

糖尿病视网膜病变的局灶性缺氧成像

• 批准号: 6643841
• 负责人: ANNE-MARIE MAMAN
• 金额: $ 10万
• 依托单位: OXYGEN ENTERPRISES, LTD
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-06-01 至 2004-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6643841
• 关键词: angiogenesis; bioimaging /biomedical imaging; biomedical equipment development; cardiovascular imaging /visualization; diabetic retinopathy; diagnosis design /evaluation; eye disorder diagnosis; hypoxia; laboratory rat; noninvasive diagnosis; oximetry; phosphorus; retinography; swine

DESCRIPTION (provided by applicant): Diabetic retinopathy is the leading cause of blindness in working age Americans. In these patients there is pathologic growth of new blood vessels in the inner retina. These poorly formed blood vessels burst, bleeding into the retina and obscuring vision. Current treatment for these patients is to detect the neovascular formations and ablate tissue around the vessels, intending to reduce or eliminate further angiogenic response. It is proposed that new blood vessels are formed in response to local tissue hypoxia, but it is not possible at this time to identify focal areas of hypoxia in the retina. Oxygen Enterprises has developed a safe, accurate and robust method that is capable of detecting focal hypoxia in tissues. Through this Phase I SBIR Grant, the company proposes to apply their technology to the understanding and measuring oxygen in the retina of the eye. Initial application will be in biomedical research. Longer term goals will be to apply this technology into clinical practice, allowing clinicians to diagnose and treat patients with diabetic retinopathy earlier and more effectively. The company proposes to develop a phosphorescence lifetime imaging system that will provide an opticalmethod for the clinician that yields a topographic map, clearly identifying focal areas of hypoxia and differentiating them from areas of normoxia. During Phase 1 the company proposes to synthesize gram quantities of a new Oxyphors (phosphor) for suitable for pre-clinical testing and to construct a minimally invasive imaging system for use in ophthalmological research. The imaging system will be assembled and adapted for measuring oxygen in the retina of two animal models, piglets and rats, and the existing imaging software will be revised into a technically competent and user-friendly operating system. Oxygen Enterprises' imaging system is expected to offer sensitive and specific detection and quantification of focal hypoxia in retinal tissue - which is anticipated to allow earlier and more accurate diagnosis of retinopathy - and a diagnostic system with high stability and reliability, providing a clear and unambiguous display of retinal pathology. Emphasis will be on making the system user friendly and on providing it at a reasonable cost.

描述（由申请人提供）：糖尿病视网膜病变是美国工作年龄人口失明的主要原因。在这些患者中，视网膜内层出现新血管的病理性生长。这些形成不良的血管破裂，出血进入视网膜并模糊视力。目前对这些患者的治疗是检测新生血管形成并消融血管周围的组织，旨在减少或消除进一步的血管生成反应。有人提出，新血管的形成是对局部组织缺氧的反应，但目前还不可能识别视网膜缺氧的焦点区域。 Oxygen Enterprises 开发了一种安全、准确且稳健的方法，能够检测组织中的局灶性缺氧。通过第一阶段 SBIR 资助，该公司提议将其技术应用于理解和测量眼睛视网膜中的氧气。最初的应用将是在生物医学研究中。长期目标是将这项技术应用于临床实践，使临床医生能够更早、更有效地诊断和治疗糖尿病视网膜病变患者。 该公司提议开发一种磷光寿命成像系统，该系统将为临床医生提供一种光学方法，生成地形图，清楚地识别缺氧的焦点区域并将其与含氧量正常的区域区分开来。 在第一阶段，该公司计划合成克数量的新型 Oxyphors（磷光体），以适合临床前测试，并构建用于眼科研究的微创成像系统。该成像系统将被组装并适应于测量两种动物模型（仔猪和大鼠）视网膜中的氧气，现有的成像软件将被修改为技术先进且用户友好的操作系统。 Oxygen Enterprises 的成像系统有望对视网膜组织中的局灶性缺氧提供灵敏、特异的检测和量化，从而能够更早、更准确地诊断视网膜病变，以及具有高稳定性和可靠性的诊断系统，提供清晰、明确的视网膜病理显示。重点是使系统变得用户友好并以合理的成本提供。